München, Germany, September 17, 2009 The Bavarian Patent Alliance GmbH and the biotech company XL-protein GmbH have signed an exclusive licensing agreement on a promising invention of the Technical University of Munich.
With the so-called “PASylation technology” the plasma half-life of biological agents is extended manifold. Therapeutic proteins are directly fused on the genetic level with sequences of the amino acids proline, alanine and serine. The “PAS” polymers are stable in plasma and pharmacologically inert. They adopt a bulky random coil structure, which significantly increases the size of the protein. Thus, the typically rapid clearance of the biological via kidney filtration is retarded by 1-2 orders of magnitude. In this way the duration of drug action in the human body can be extended to several days.
Through the acquisition of the worldwide patent rights XL-protein takes, as the exclusive licensee, advantage of the PASylation technology originally developed at the Institute of Biological Chemistry at the Technical University of Munich (TUM).
Download full press release (only available in German)